Supply Chain Intelligence

Coherus Oncology, Inc. Supply Chain

CHRS supply chain intelligence for Coherus Oncology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CHRS ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

18Suppliers
30Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Coherus Oncology, Inc. (CHRS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

59Total relationships
3Distinct source URLs
9High confidence
0.721Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Coherus Oncology, Inc. Suppliers

TickerNameConfidenceEvidence
JUNSHI-BIOSCIENCES JUNSHI-BIOSCIENCES 92% We are obligated to pay Junshi Biosciences a royalty in the low twenty percent range on net sales of LOQTORZI and up to an aggregate $380.0 million in one-time payments for the achievement of various…
AMRX Amneal Pharmaceuticals, Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
AMRX Amneal Pharmaceuticals, Inc. 72% Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN grap…
AZN AstraZeneca PLC 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
BMY Bristol-Myers Squibb Company 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions …
BMYMP Bristol-Myers Squibb Co 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
FMS Fresenius Medical Care AG 72% Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
FMS Fresenius Medical Care AG 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r…
GILD Gilead Sciences, Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
MRK Merck & Co., Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r…
REGN Regeneron Pharmaceuticals, Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
KLTO Klotho Neurosciences Inc 62% Reciprocal relationship from KLTO graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from KLTO graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from KLTO g…

Coherus Oncology, Inc. Customers

TickerNameConfidenceEvidence
CAH Cardinal Health, Inc. 95% e employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduction in force consisted of $ million in c…
CAH Cardinal Health, Inc. 95% Reciprocal relationship from CAH graph: Reciprocal relationship from CHRS graph: e employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restruc…
MCK McKesson Corporation 95% Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MCK grap…
MCK McKesson Corporation 95% revenue was generated in the United States. The Company’s net revenue was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) ​ ​ ​ 2025 ​ 2024 LOQTORZI ​ $ 40,836 ​ $ …
APOTEX APOTEX 90% we granted to Apotex an exclusive license under our rights to toripalimab to commercialize toripalimab within Canada
AMRX Amneal Pharmaceuticals, Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
AMRX Amneal Pharmaceuticals, Inc. 72% Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers …
AZN AstraZeneca PLC 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN grap…
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMY grap…
BMY Bristol-Myers Squibb Company 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
BMYMP Bristol-Myers Squibb Co 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from BMYM…
FMS Fresenius Medical Care AG 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
FMS Fresenius Medical Care AG 72% Reciprocal relationship from FMS graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions re…
GILD Gilead Sciences, Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
GILD Gilead Sciences, Inc. 72% Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions r…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (v…
MRK Merck & Co., Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
REGN Regeneron Pharmaceuticals, Inc. 72% plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of our products (via a team of Fiel…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from REGN g…
BIOPHARMA-CREDIT-PLC BIOPHARMA-CREDIT-PLC 62% urchaser Group’s right to receive the Revenue Payment terminates and the Company no longer has the obligation to pay Revenue Payments once the Purchaser Group receives the amount equal to 2.25 times …
BPCR-LIMITED BPCR-LIMITED 62% costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. 98 Table of Contents On October 27, 2023, LOQTORZI was approved by the FDA in combination with ci…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% he right to conduct all commercial activities of LOQTORZI in the United States and Canada. We have paid $25.0 million for the achievement of certain milestones, and we pay a royalty in the low twenty…
CODUET-ROYALTY-HOLDINGS-LLC CODUET-ROYALTY-HOLDINGS-LLC 62% costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. 98 Table of Contents On October 27, 2023, LOQTORZI was approved by the FDA in combination with ci…
COMPANY-ANKURA-TRUST-COMPANY-LLC COMPANY-ANKURA-TRUST-COMPANY-LLC 62% duction in trade receivables. (2) This balance is expected to be settled in a front-weighted fashion over the remainder of 2026 and into 2027. 18 Table of Contents ​ Cash flows from continuing operat…
COMPANY-LLC COMPANY-LLC 62% . On April 15, 2025, the Company paid $ 170.0 million in cash to repurchase $ 170.0 million aggregate principal amount of the 2026 Convertible Notes in privately negotiated transactions. On May 15, 2…
COMPUTERSHARE-TRUST-COMPANY COMPUTERSHARE-TRUST-COMPANY 62% with the development and commercialization of our product candidates and the extent to which we may enter into additional agreements with third parties to participate in their development and commerc…
CONDUET-ROYALTY-HOLDINGS-LLC CONDUET-ROYALTY-HOLDINGS-LLC 62% duction in trade receivables. (2) This balance is expected to be settled in a front-weighted fashion over the remainder of 2026 and into 2027. 18 Table of Contents ​ Cash flows from continuing operat…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% inancial institutions. Actual events involving reduced or limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the finan…

Coherus Oncology, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CHRS-DEBT-8637 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
CHRS-DEBT Debt stack $73.7M 90% Market cache reports total debt of $73.7M.

Coherus Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Coherus Oncology, Inc..

Coherus Oncology, Inc. Ownership

HolderNameConfidenceEvidence
CHRS-OWNER-BARCLAYS-PLC BARCLAYS PLC 90% 13F overlay lists BARCLAYS PLC as top holder; 156 tracked holders.

Coherus Oncology, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ALLO Allogene Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 1 ['customer', 'supplier']
CTNM Contineum Therapeutics, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
AMRX Amneal Pharmaceuticals, Inc. 100.00 1 ['customer', 'supplier']
CVS CVS Health Corporation 100.00 2
AVIR Atea Pharmaceuticals, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
DEO Diageo plc 100.00 2
AZN AstraZeneca PLC 100.00 1 ['customer', 'supplier']
CABA Cabaletta Bio, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Coherus Oncology, Inc..

Unlock full CHRS data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
CHRS
Unlock CHRS Supply Chain Data
Verified relationships include:
JUNSHI-BIOSCIENCESJUNSHI-BIOSCIENCESSupplier92%
AMRXAmneal Pharmaceuticals, Inc.Supplier72%
CAHCardinal Health, Inc.Customer95%
CAHCardinal Health, Inc.Customer95%
+47 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →